Clinical trials: Asthma Patients
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Mild Persistent Asthma
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.
- Trial name
- NCT02584257
- Testing
- methacholine chloride, ProAir HFA, Lupin albuterol HFA MDI
- Where
- 17 sites in United States
- Volunteers
- 217 people
- Sponsor
- Lupin, Inc.
Asthma
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.
- Trial name
- KIA (NCT01097694)
- Testing
- Imatinib mesylate
- Where
- 7 sites in United States
- Volunteers
- 176 people
- Sponsor
- Brigham and Women's Hospital
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Asthma
Telecommunications System in Asthma
This project is investigating whether application of a telecommunications system to the care of adult patients with asthma will improve self-management by enhancing compliance with preventive medication regimens and fostering the…
- Trial name
- NCT00232557
- Testing
- TLC-Asthma, TLC-health education
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- US Department of Veterans Affairs
Asthma
Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)
Open label, 12-week clinical trial to assess efficacy, safety, treatment adherence and Quality of Life impact of Mometasone Furoate dry powder 400 mcg once-daily in persistent mild-moderate asthmatic patients at least 12 years…
- Trial name
- APEGO (NCT00687531)
- Testing
- Mometasone Furoate
- Volunteers
- 385 people
- Sponsor
- Organon and Co
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).
- Trial name
- NCT02134028
- Testing
- Dupilumab
- Where
- 365 sites in United States, Argentina and 25 more
- Volunteers
- 2,282 people
- Sponsor
- Sanofi
Asthma
Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)
The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate.
- Trial name
- NCT00306163
- Testing
- Ciclesonide, Fluticasone
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Asthma
BI 671800 ED in Steroid-naive Asthmatic Patients
This is a 6 week study to investigate the effectiveness and safety of BI 671800 ED in patients with asthma who do not take inhaled corticosteroids.
- Trial name
- NCT01092143
- Testing
- BI 671800, Fluticasone propionate
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
- Trial name
- NCT01854047
- Testing
- Dupilumab, ICS/LABA therapy, Salbutamol/albuterol
- Where
- 201 sites in United States, Argentina and 14 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Asthma
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic…
- Trial name
- NCT00452348
- Testing
- Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
- Where
- 81 sites in United States, Argentina and 3 more
- Volunteers
- 628 people
- Sponsor
- GlaxoSmithKline
Asthma
MGR001 / Advair Diskus Local Equivalence Study in Asthma
The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients
- Trial name
- NCT02245672
- Testing
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- Where
- 101 sites in United States
- Volunteers
- 1,128 people
- Sponsor
- Mylan Pharma UK Ltd.
Asthma
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1…
- Trial name
- NCT00837967
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
This is a multicentre, randomized, single-blind, active-controlled, parallel-group phase III local registration study for a treatment period of 12 weeks.
- Trial name
- NCT01687283
- Testing
- fluticasone propionate inhalation solution, budesonide suspension
- Where
- 25 sites in China
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Investigate the Efficacy of Symbicort® SMART.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus…
- Trial name
- SAKURA (NCT00839800)
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 109 sites in Argentina, Brazil and 10 more
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline